Evolus: Chiseling Away At The Aesthetic Market [Seeking Alpha]
Evolus, Inc. (EOLS)
Last evolus, inc. earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
us.evolis.com/investor-relations
Company Research
Source: Seeking Alpha
The company is expanding its product portfolio by adding dermal fillers through exclusive agreements with Evolysse and Estyme. The market opportunity for Evolus is significant, with the neurotoxin market estimated at $3.5 billion and the dermal fillers market at $2.5 billion. Strong revenue growth, expanding product line, and imminent profitability present an attractive opportunity for a speculative small-cap stock that can potentially double. Overview Evolus ( NASDAQ: EOLS ) is a facial beauty company in the aesthetic neurotoxin market. The flagship product at this time is Jeuveau (prabotulinumtoxinA-xvfs), the first approved neurotoxin exclusively for aesthetic use. Jeuveau is a 900 kDa Recommended For You Recommended For You About EOLS Stock More on EOLS Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EOLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EOLS alerts
High impacting Evolus, Inc. news events
Weekly update
A roundup of the hottest topics
EOLS
News
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain [Yahoo! Finance]Yahoo! Finance
- Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in SpainBusiness Wire
- Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan [Yahoo! Finance]Yahoo! Finance
- Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physicians [Yahoo! Finance]Yahoo! Finance
EOLS
Earnings
- 5/7/24 - Miss
EOLS
Sec Filings
- 6/11/24 - Form 8-K
- 6/6/24 - Form 4
- 6/6/24 - Form 144
- EOLS's page on the SEC website